From the record

European Medicines Agency committee backs Revolution Medicines' pancreatic cancer drug Rasonque, bringing it closer to EU approval.

Items older than 7 days — their verdicts, sources and coverage history — are part of the Azimuth Daily record and available to signed-in readers.